Interferons in vitreoretinal diseases; a review on their clinical application, and mechanism of action

De Veer MJ, Holko M, Frevel M, Walker E, Der S, Paranjape JM et al (2001) Functional classification of interferon-stimulated genes identified using microarrays. J Leukoc Biol 69(6):912–920

Article  PubMed  Google Scholar 

Medrano RF, Hunger A, Mendonça SA, Barbuto JAM, Strauss BE (2017) Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. Oncotarget 8(41):71249

Article  PubMed  PubMed Central  Google Scholar 

Albini A, Marchisone C, Del Grosso F, Benelli R, Masiello L, Tacchetti C et al (2000) Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: a gene therapy approach. Am J Pathol 156(4):1381–1393

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE et al (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4(1):63–68

Article  CAS  PubMed  Google Scholar 

Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al (2003) IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1):69–77

Article  CAS  PubMed  Google Scholar 

Wang H, Hu H, Zhang K (2017) Overview of interferon: characteristics, signaling and anti-cancer effect. Arch Biotechnol Biomed 1:1–16

Article  Google Scholar 

Lee AJ, Ashkar AA (2018) The dual nature of type I and type II interferons. Frontiers in immunology, 2061

Lazear HM, Schoggins JW, Diamond MS (2019) Shared and distinct functions of type I and type III interferons. Immunity 50(4):907–923

Article  CAS  PubMed  PubMed Central  Google Scholar 

Platanias LC (2005) Mechanisms of type-I-and type-II-interferon-mediated signalling. Nat Rev Immunol 5(5):375–386

Article  CAS  PubMed  Google Scholar 

Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KC (2010) Antiproliferative properties of type I and type II interferon. Pharmaceuticals 3(4):994–1015

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yoshimura T, Sonoda K-H, Sugahara M, Mochizuki Y, Enaida H, Oshima Y et al (2009) Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS ONE 4(12):e8158

Article  PubMed  PubMed Central  Google Scholar 

Banerjee S, Savant V, Scott RA, Curnow SJ, Wallace GR, Murray PI (2007) Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders. Invest Ophthalmol Vis Sci 48(5):2203–2207

Article  PubMed  Google Scholar 

Afarid M, Lashkarizadeh H, Ashraf MJ, Nowroozzadeh MH, Shafiee SM (2016) The efficacy of intravitreal interferon alpha-2b for the treatment of experimental endotoxin-induced uveitis. Indian J Ophthalmol 64(5):376

Article  PubMed  PubMed Central  Google Scholar 

Afarid M, Meshksar A, Salehi A, Safarpour MM (2020) Evaluation of the effect of topical interferon α2b as a complementary treatment of macular edema of patients with diabetic retinopathy: a double-blind placebo-controlled randomized clinical trial study. Retina 40(5):936–942

Article  CAS  PubMed  Google Scholar 

Afarid M, Azimi A, Malekzadeh M (2019) Evaluation of serum interferons in patients with age-related macular degeneration. J Res Med Sci Official J Isfahan Univ Med Sci 24:24

CAS  Google Scholar 

Kötter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Günaydin I et al (2003) Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87(4):423–431

Article  PubMed  PubMed Central  Google Scholar 

Krause L, Turnbull JR, Torun N, Pleyer U, Zouboulis CC, Foerster MH (2004) Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet’s disease. Adamantiades-Behçet’s Disease, 511–9

Sobacı G, Erdem Ü, Durukan AH, Erdurman C, Bayer A, Köksal S et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology 117(7):1430–1435

Article  PubMed  Google Scholar 

Park J-Y, Chung Y-R, Lee K, Song JH, Lee E-S (2015) Clinical experience of interferon alfa-2a treatment for refractory uveitis in Behcet’s disease. Yonsei Med J 56(4):1158–1162

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bielefeld P, Devilliers H, Deschasse C, Saadoun D, Sève P, Muselier A et al (2016) Potential of pegylated interferon alpha-2a in Behçet uveitis: a report of five cases. Ocul Immunol Inflamm 24(5):599–602

PubMed  Google Scholar 

Lee JH, Lee CS, Lee SC (2018) Interferon alpha-2a treatment for refractory Behcet uveitis in Korean patients. BMC Ophthalmol 18(1):1–4

Article  CAS  Google Scholar 

Eser-Ozturk H, Sullu Y (2019) The results of interferon-alpha treatment in Behçet uveitis. Ocular Immunol Inflamm

Celiker H, Kazokoglu H, Direskeneli H (2019) Long-term efficacy of pegylated interferon alpha-2b in Behçet’s uveitis: a small case series. Ocul Immunol Inflamm 27(1):15–22

Article  CAS  PubMed  Google Scholar 

Yalçindag N, Köse HC (2020) Comparison of the treatment results for Behçet uveitis in patients treated with infliximab and interferon. Ocul Immunol Inflamm 28(2):305–314

Article  PubMed  Google Scholar 

Atik BK, Altan Ç, Başarir B (2020) Therapeutic outcomes of interferon-alpha-2a treatment in Behçet uveitis Turkiye. Klinikleri J Ophthalmol 29(4):294–299

Article  Google Scholar 

Qian Y, Qu Y, Gao F, Pei M, Liang A, Xiao J et al (2021) Comparison of the safety and efficacy of interferon alpha-2a and cyclosporine-a when combined with glucocorticoid in the treatment of refractory Behçet’s uveitis: a randomized controlled prospective study. Front Pharmacol 12:699903

Article  CAS  PubMed  PubMed Central  Google Scholar 

Becker M, Heiligenhaus A, Hudde T, Storch-Hagenlocher B, Wildemann B, Barisani-Asenbauer T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89(10):1254–1257

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mackensen F, Jakob E, Springer C, Dobner BC, Wiehler U, Weimer P et al (2013) Interferon versus methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am j ophthalmol 156(3):478–486

Article  CAS  PubMed  Google Scholar 

Plskova J, Greiner K, Forrester JV (2007) Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am j ophthalmol 144(1):55–61

Article  CAS  PubMed  Google Scholar 

Yalcinbayir O, Yucel AA, Kaderli B, Gelisken O (2009) Subconjunctival interferon α-2a application in a case with serpiginous choroidopathy. Retinal Cases Brief Rep 3(2):214–217

Article  Google Scholar 

Kirkpatrick J, Dick A, Forrester J (1993) Clinical experience with interferon alfa-2a for exudative age-related macular degeneration. British j Ophthal 77(12):766–770

Brasnu E, Wechsler B, Bron A, Charlotte F, Bliefeld P, Lehoang P et al (2005) Efficacy of interferon-α for the treatment of Kaposi’s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140(4):746–748

Article  CAS  PubMed  Google Scholar 

Invernizzi A, Iannaccone F, Marchi S, Mastrofilippo V, Coassin M, Fontana L, et al (2018) Interferon alpha-2a for the treatment of post-infectious uveitis secondary to presumed intraocular tuberculosis. Ocular Immunol Inflamm

Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis?: A pilot study. Retina 26(7):786–791

Article  PubMed  Google Scholar 

Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93(7):906–913

Article  CAS  PubMed  Google Scholar 

Maleki A, Aghaei H, Lee S (2018) Topical interferon alpha 2b in the treatment of refractory pseudophakic cystoid macular edema. Am J Ophthalmol Case Rep 10:203–205

Article  PubMed  PubMed Central  Google Scholar 

Deuter CM, Fausel J, Doycheva D, Zierhut M (2019) Long-term results of therapy with interferon alpha in chronic uveitic macular edema. Invest Ophthalmol Visual Sci 60(9):3515

Google Scholar 

Dimopoulos S, Deuter CM, Blumenstock G, Zierhut M, Dimopoulou A, Voykov B, et al (2019) Interferon alpha for refractory pseudophakic cystoid macular edema (irvine-gass syndrome). Ocular Immunol Inflamm

Aksu-Ceylan N, Cebeci Z, Altinkurt E, Kir N, Oray M, Tugal-Tutkun I (2021) Interferon Alpha-2a for the treatment of cystoid macular edema secondary to acute retinal necrosis. Ocular Immunol Inflamm, 1–10

Maleki A, Stephenson AP, Hajizadeh F (2020) Topical interferon alpha 2b in the treatment of refractory diabetic macular edema. J Ophthalmic Vis Res 15(4):453

PubMed  PubMed Central  Google Scholar 

Faghihi H, Inanloo B, Mirzaee A, Fadakar K, Mirshahi A, Ebrahimiadib N et al (2022) Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema. International Journal of Retina and Vitreous 8(1):1–9

Article  Google Scholar 

Couret C, Servant M, Lebranchu P, Hamidou M, Weber M (2020) Efficacy and safety of interferon alpha 2a and pegylated interferon alpha 2a in inflammatory macular edema. Ocul Immunol Inflamm 28(2):329–336

Article  CAS  PubMed  Google Scholar 

Skowsky WR, Siddiqui T, Hodgetts D, Lambrou FH Jr, Stewart MW, Foster MT Jr (1996) A pilot study of chronic recombinant interferon-alfa 2a for diabetic proliferative retinopathy: metabolic effects and opthalmologic effects. J Diabetes Complications 10(2):94–99

Article  CAS  PubMed  Google Scholar 

Fardeau C,

留言 (0)

沒有登入
gif